Oncotarget

Oncotarget. 9(31): 22236-22240

Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature

Anne Heisig¹, Jan Sörensen², Stefanie-Yvonne Zimmermann¹, Stefan Schöning¹, Dirk Schwabe¹, Hans-Michael Kvasnicka³, Raphaela Schwentner⁴, Caroline Hutter⁴, Thomas Lehrnbecher¹

¹ Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany

² Division of Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany

³ Institute of Pathology, Johann Wolfgang Goethe-University, Frankfurt, Germany

⁴ St. Anna Kinderspital, Vienna, Austria

Correspondence to:Thomas Lehrnbecher,Thomas.Lehrnbecher@kgu.de

Copyright: © 2018 Heisig et al.

DOI: 10.18632/oncotarget.25277

Published online: 24 April 2018

Abstract

Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem to cure the patients, and it is unknown, when and how to stop vemurafenib treatment. We present a girl with severe multisystem LCH who responded only to vemurafenib. After 8 months of treatment, vemurafenib was tapered and replaced by prednisone and vinblastine, a strategy which has not been described to date. Despite chemotherapy, early relapse occurred, but remission was achieved by re-institution of vemurafenib. Further investigation needs to address the optimal duration of vemurafenib therapy in LCH and whether and which chemotherapeutic regimen may prevent disease relapse after cessation of vemurafenib.

INTRODUCTION

Langerhans cell Histiocytosis (LCH) is a rare malignant disease. The clinical course is highly variable, ranging from self-limiting local disease to a rapidly progressive multisystem disorder that may lead to death [1]. A mutation in the BRAF gene, creating a BRAFV600E mutant protein, can be found in a number of malignant diseases and is considered a driver mutation in a proportion of LCH patients [2, 3]. The mutation is associated with risk organ involvement, a more severe course of disease, poorer response to therapy, as well as a higher risk of disease relapse [4–6]. Although chemotherapy is the mainstay of LCH treatment, detection of BRAF mutation extends therapeutic options including selective BRAF inhibitors, such as vemurafenib [3]. The compound is not approved for this indication, but several reports have suggested its efficacy in patients with LCH [6–12]. Although vemurafenib seems to be a potent drug in order to stabilize the clinical condition of these patients, current data suggest that vemurafenib monotherapy cannot cure patients with LCH. In addition, to date, the optimal treatment duration with vemurafenib remains poorly defined, as well as whether adding chemotherapy to vemurafenib or replacing the compound with chemotherapy is of any benefit. Interestingly, measurement of circulating cell-free DNA of BRAFV600E mutant alleles in peripheral blood has been reported as a promising biomarker in LCH, but it is unclear whether the assessment could help in decision making regarding vemurafenib therapy [6].

CASE REPORT

A 2 3/12-year-old girl was admitted to the hospital in poor general condition with persisting fever of unknown origin. The previous history of the patient and the family was uneventful. Clinical examination revealed cervical lymphadenopathy, scaly retro-auricular skin lesions and hepatosplenomegaly (3 cm and 5 cm below costal margin, respectively). Laboratory findings demonstrated pancytopenia (hemoglobin 7.1 g/dl, leucocytes 3.23/nl, platelets 68/nl), elevated inflammation markers (C-reactive protein 2.74 mg/dl, soluble IL-2 receptor (sCD25) >22,500U/ml) and low total protein (5.3 g/dl). No malignant cells were detected in the bone marrow. Despite empirical therapy with broad-spectrum antibiotics, immunoglobulins and methyl-prednisolone, the clinical situation rapidly deteriorated [disease activity score (DAS) 19] (Figure 1A and 1B) [13]. LCH was diagnosed by histopathological and immunohistochemical examination of the cervical lymph node, but despite the administration of prednisone, vinblastine and etoposide, the clinical condition further aggravated and the patient required daily transfusions of red blood cells, platelets and albumin. After the BRAFV600E mutation was demonstrated in the biopsy specimen, vemurafenib (15 mg/kg twice daily) was initiated, which resulted in a rapid clinical improvement. Within several days, the girl defervesced, liver and spleen almost normalized in size, and no further transfusions were required (DAS 2).

Figure 1View larger versionFigure 1. Levels of hemoglobin and C-reactive protein (CRP) (A), platelets (B) and percentage of the BRAF V600E cells in the peripheral blood (C) of a patient with severe multisystem Langerhans cell Histiocytosis receiving different treatment regimens including vemurafenib.

Over the next months, the girl stayed on vemurafenib monotherapy, which was well tolerated except for mild photosensitivity and alopecia. With informed consent of the parents, DNA was isolated from whole blood using the QIAamp DNA blood mini kit (Qiagen, Germany) and allele-specific PCR was performed at irregular time points to assess levels of BRAF mutant alleles which were slowly decreasing (Figure 1C) [12]. After 8 months of stable DAS of 1, we thought to stop vemurafenib due to the unknown long-term side effects. However, we aimed to replace vemurafenib by conventional LCH treatment with prednisone (40 mg/m²/d) and vinblastine (6 mg/m²/week). Therefore, we added both compounds while sustaining vemurafenib therapy, which was then tapered and finally stopped after 7 weeks of combination treatment. One week after cessation of vemurafenib, the girl developed fever and hepatosplenomegaly, and laboratory evaluation demonstrated pancytopenia and rising inflammatory markers. Vemurafenib treatment was re-initiated, resulting in a second complete remission and normal laboratory findings within several days. The girl is currently being prepared for allogeneic hematopoietic stem cell transplantation.

DISCUSSION

The selective BRAF kinase inhibitor vemurafenib may be an effective therapeutic option in diseases with a BRAFV600E mutation, which can be detected in almost 60% of patients with LCH [3]. To date, there are published reports on 7 adolescents older than 16 years and adults as well as on 7 children with LCH receiving vemurafenib (Table 1) [6–12]. All of them experienced a rapid partial or even complete clinical response. While these data seem encouraging, there may be a substantial publication bias favoring an efficacy of vemurafenib. Still, our patient responded exceedingly well. The patients reported received vemurafenib between 3 months up to 40 months, but it has to be noted that the optimal duration of therapy with vemurafenib remains unclear. Vemurafenib was discontinued in 7 patients, all of them developed disease reactivation. As the compound exerts skin and liver toxicity, is associated with increased risk of squamous cell carcinoma and as there are no data on the long-term risks, in particular in young children, we sought to terminate vemurafenib treatment [14]. In order to prevent disease reactivation, we first added standard chemotherapy with prednisone and vinblastine, and tapered vemurafenib thereafter, an approach which has not been reported to date. The combination of vemurafenib with LCH standard chemotherapy was well tolerated. No reactivation occurred during the tapering phase. However, after stopping vemurafenib, the patient relapsed within several days, indicating that standard chemotherapy was not useful to suppress or even to eradicate the LCH BRAFV600E positive clone and thus to prevent relapse. In contrast, in this situation, re-institution of vemurafenib treatment was effective, as it was reported in all comparable patients (Table 1) [6, 11, 12]. Whether a more intensive chemotherapy, e.g. the administration of cytarabine or 2-CDA might prevent relapse with acceptable toxicity needs to be addressed in the future, but it might be possible that in these patients, conventional therapy will not have an effect at all.

See full table Table 1. Published data on patients receiving vemurafenib for Langerhans cell Histiocytosis (LCH)

The level of BRAF mutant alleles in peripheral blood has been suggested as a marker for therapeutic response and may help to guide therapy [6, 12]. In our patient, BRAF mutant alleles remained detectable in peripheral blood throughout, even in the clinically stable patient after several months of vemurafenib treatment. BRAF mutant alleles were not quantified in the bone marrow, and it remains unresolved where the LCH clone was which caused relapse. It is unclear whether continuously positive BRAF levels in peripheral blood indicate highest risk of relapse. The fact that BRAF levels further decreased after vemurafenib was stopped and the patient already developed clinical signs of disease reactivation suggests that BRAF levels have a considerable time lag. On the other hand, BRAF levels were lowest after combination treatment with vemurafenib, prednisone and vinblastine, which might indicate that this regimen was more effective than vemurafenib alone, and one is prompted to speculate whether prolonged combination treatment could have prevented relapse. Nevertheless, it remains to be evaluated whether the assessment of BRAF levels at certain time points of therapy might help to stratify the intensity of treatment as it has been shown for minimal residual disease in acute lymphoblastic leukemia [15].

In conclusion, vemurafenib seems to be a powerful treatment option in patients with severe multisystem LCH, even during relapse. Further investigation needs to address 1) the optimal duration of vemurafenib therapy, 2) whether and which chemotherapeutic regimen may help to prevent disease relapse after cessation of vemurafenib and 3) the value of BRAF levels in guiding therapy.

Footnotes

CONFLICTS OF INTEREST

The authors of this manuscript have no conflicts of interest to declare.

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

PMC Copyright Notice

The articles available from the PMC site are protected by copyright, even though access is free. Copyright is held by the respective authors or publishers who provide these articles to PMC. Users of PMC are responsible for complying with the terms and conditions defined by the copyright holder.

Users should assume that standard copyright protection applies to articles in PMC, unless an article contains an explicit license statement that gives a user additional reuse or redistribution rights. PMC does not allow automated/bulk downloading of articles that have standard copyright protection.

See the copyright notice on the PMC site, https://www.ncbi.nlm.nih.gov/pmc/about/copyright/, for further details and specific exceptions.

REFERENCES

Nezelof C, Basset F, authors. Langerhans cell histiocytosis research. Past, present, and future. Hematol Oncol Clin North Am. 1998;12:385–406. [PubMed]

Egeler RM, Katewa S, Leenen PJ, Beverley P, Collin M, Ginhoux F, Arceci RJ, Rollins BJ; Steering Committee of the Nikolas Symposium, authors. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci. Pediatr Blood Cancer. 2016;63:1704–1712. [PubMed]

Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, et al., authors. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–1923. [PubMed]

Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, et al., authors. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211:669–683. [PubMed]

Heritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clement C, Dijoud F, Rigau V, Moshous D, et al., authors. BRAF mutation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016;34:3023–3030. [PubMed]

Heritier S, Helias-Rodzewicz Z, Lapillonne H, Terrones N, Garrigou S, Normand C, Barkaoui MA, Miron J, Plat G, Aladjidi N, Pagnier A, Deville A, Gillibert-Yvert M, et al., authors. Circulating cell-free BRAF(V600E) as a biomarker in children with Langerhans cell histiocytosis. Br J Haematol. 2017;178:457–467. [PubMed]

Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steinestel K, Bruderlein S, Cario H, Lubatschofski A, Welke C, Anagnostopoulos I, Barth TF, Beer AJ, Moller P, et al., authors. Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget. 2014;5:4060–4070. . https://doi.org/10.18632/oncotarget.2061. [PubMed]

Charles J, Beani JC, Fiandrino G, Busser B, authors. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation. J Am Acad Dermatol. 2014;71:e97–99. [PubMed]

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martinez-Valle F, et al., authors. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol. 2018;4:384–388. [PubMed]

Gandolfi L, Adamo S, Pileri A, Broccoli A, Argnani L, Zinzani PL, authors. Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor. J Natl Compr Canc Netw. 2015;13:715–718. [PubMed]

Heritier S, Jehanne M, Leverger G, Emile JF, Alvarez JC, Haroche J, Donadieu J, authors. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncol. 2015;1:836–838. [PubMed]

Kolenova A, Schwentner R, Jug G, Simonitsch-Klupp I, Kornauth C, Plank L, Horakova J, Bodova I, Sykora T, Geczova L, Holter W, Minkov M, Hutter C, authors. Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. Blood Adv. 2017;1:352–356. [PubMed]

Donadieu J, Piguet C, Bernard F, Barkaoui M, Ouache M, Bertrand Y, Ibrahim H, Emile JF, Hermine O, Tazi A, Genereau T, Thomas C, authors. A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43:770–776. [PubMed]

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandala M, et al., authors. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders’ analysis. Eur J Cancer. 2017;79:176–184. [PubMed]

Schrappe M, author. Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014;2014:244–249. [PubMed]

[Back]

Figure 1.

Levels of hemoglobin and C-reactive protein (CRP) (A), platelets (B) and percentage of the BRAF V600E cells in the peripheral blood (C) of a patient with severe multisystem Langerhans cell Histiocytosis receiving different treatment regimens including vemurafenib.

[Back]

[Back]

Table 1. Published data on patients receiving vemurafenib for Langerhans cell Histiocytosis (LCH)

Author, year
Number of Patients; age/gender
Disease extent
Treatment prior to Vemurafenib (Duration)
Vemurafenib treatment
Current / last reported Status

Dose and duration
Response to vemurafenib
Treatment duration/Discontinuation of vemurafenib
Relapse after discontinuation

Bubolz et al. 2014
1
45 yrs/f
Multisystem
1) Steroids + VBL (1month, repeated after 4 months)
2) Cladribine (3 months)
240 mg, increased to 960mg
Partial
3 months / Yes
Yes
Progression of disease

Charles et al. 2014
1
>90 yrs/f
Skin
1) Steroids (NS)
2) Thalidomide (NS)
960mg
Complete
>6 months / No

Remission

Diamond et al. 2017
4
> 16 yrs/NS
NS
NS
All 960mg
Complete (1 pt)
Partial (3 pts)
15-40 months / NS

1x CML
1x thyroid cancer
2x remission

Gandolfi et al. 2015
1
40 yrs/f
Skin, skull
1) Radiotherapy (30Gy) (NS)
2) MACOP-B (NS)
3) VNCOP-B (NS)
4) IEV (2 cycles)
5) BEAM (NS)
6) Bendamustine (6 cycles)
1920mg, reduced to
1440mg
Partial
10 months / No

Progression on vemurafenib after 10 months

Héritier et al. 2015
1
8 mths/f
Multisystem
1) Steroids + VBL (2 inductions)
2) Cladribine (1 course)
33.8mg/kg, reduced to 8.5mg/kg
Complete
4 months / Yes
Yes
Remission after re-institution of vemurafenib

Héritier et al. 2017
5
<3 yrs/NS
Multisystem
Steroids + VBL (1 induction)
NS
Partial / complete
NS / Yes (4 pts)
No (1 pt)
Yes (all of 4 pts)
Remission after re-institution of vemurafenib

Kolenova et al. 2017
1
15 mths/m
Multisystem
1) Steroids + VBL (6 weeks)
2) Maintenance (2 weeks)
2) Cladribine (4 cycles)
2x10mg/kg, increased to 2x15mg/kg, then reduced to 10mg/kg
Complete
8 months / Yes
Yes
Remission after re-institution of vemurafenib, then HSCT

Own patient
1
2 yrs/f
Multisystem
Steroids + VBL
(4 weeks) Etoposide
2x15 mg/kg
Complete
8 months / Yes
Yes
Remission after re-institution of vemurafenib

Yrs years; mths months; f female; m male; NS not specified; VBL vinblastine; pt(s) patient(s); MACOP-B doxorubicin, methotrexate, cyclophosphamide, vincristine, prednisone, bleomycin; VNCOP-B doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; IEV ifosfamide, epirubicin, etoposide; BEAM carmustine, etoposide, cytarabine, melphalan; Maintenance mercaptopurine vinblastine, prednisolone; CML chronic myeloid leukemia; HSCT hematopoietic stem cell transplantation.

[Back]